Huma Valuation, Funding & Investors

Huma is valued at $1B as of July 2024.

See full Huma profile

Last Huma valuation

$1B

Series D · Jul 2024

Last Huma funding round

$80M

Series D · Jul 2024

Cumulative funding Huma raised

$292M

across 6 funding rounds

Key investors in Huma

  • Leaps by Bayer
  • Hitachi Ventures
  • AstraZeneca
  • Healthbox
  • NWS Holdings
  • HAT Sicaf

Huma Overview

About Huma

Huma is a global health technology company offering a modular platform for digital hospitals at home across various disease areas. The platform employs predictive algorithms, digital biomarkers, and real-world data from hospital databases, patient wearables, and mobile devices to enable real-time information delivery to healthcare providers. London-headquartered Huma advances proactive and predictive care models through seamless data integration.


Founded

2011

HQ

United KingdomLondon

Website

huma.com

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

Valuation

$1B (Jul 2024)

Huma Valuation

Huma is currently valued at $1B, based on its Series D in July 2024. Read the announcement ↗

The $80M round included AstraZeneca, HAT Sicaf, Leaps by Bayer and Hitachi Ventures.

Huma valuation by funding round

Huma valuation by funding round
DateStageValuation
Jul 2024Series D$1B

Huma Funding History

Huma has raised a total of $292M across 6 funding rounds.

Huma's first fundraising round was a $1M seed round in January 2016. The most recent completed round was a $80M Series D in July 2024.

Huma funding rounds

Huma funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Jul 2024Series DAstraZeneca; HAT Sicaf; Leaps by Bayer; Hitachi Ventures$80M$1BHuma raised more than USD 80 million in a Series D round announced in July 2024, lifting its total capital raised to over USD 300 million. Investors included AstraZeneca, Hat Technology Fund 4 managed by HAT SGR, HV Fund by Hitachi Ventures and Leaps by Bayer. HSBC advised Huma on the fundraising. Alongside the round, the company launched the Huma Cloud Platform, a no-code, cloud-agnostic framework that lets developers build disease-management tools from pre-built modules and device connections, and host predictive and diagnostic AI algorithms. Huma, a London company founded by Dan Vahdat, supplies remote patient monitoring, companion apps and digital clinical trials. HAT had already taken part in its Series C round in 2021.
Mar 2022Strategic investmentAstraZeneca (lead)$33M--
May 2021Series CHitachi Ventures (lead); Leaps by Bayer (lead); Unilever Ventures; Samsung NEXT; Nikesh Arora; HAT Sicaf; Michael Diekmann; Sony Innovation Fund$100M-Huma closed a Series C round of USD 130 million in May 2021, made up of USD 100 million of equity and USD 30 million of credit, with an option to extend to USD 200 million through a further USD 70 million of equity. The round was co-led by Leaps by Bayer and Hitachi Ventures, with Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures, the HAT Technology & Innovation Fund of the HAT group, and individuals including Nikesh Arora and Michael Diekmann. Huma planned to use the funds for research and development, new biomarkers, expansion in the US and Asia, and decentralised clinical trials. The London company, founded in 2011 by Dan Vahdat, combines predictive algorithms, biomarkers and patient data from wearables for remote monitoring and research. Bayer had led its USD 25 million Series B in 2019.
Nov 2019Series BLeaps by Bayer (lead); NWS Holdings; Healthbox$50M--
Feb 2018Series ANWS Holdings (lead)$28M-Huma (formerly Medopad) is a UK-based digital health platform company that develops modular solutions for remote patient monitoring, predictive algorithms, digital biomarkers, and real-world data to enable 'hospitals at home' and decentralized clinical trials. This followed earlier funding and preceded a Series B of $50 million in November 2019 led by Leaps by Bayer. The company has since grown significantly, completing a Series C round of approximately $130 million in 2021 led by Leaps by Bayer and Hitachi Ventures, with participation from Samsung Next, Sony Innovation Fund, Unilever Ventures, and others, bringing total financing over $200 million including a $70 million commitment. Funds supported expansion in the US, Asia, and Middle East. Huma was named Europe's fastest-growing healthcare company by the Financial Times around that time. Later rounds included a corporate round of GBP 25 million in March 2022 led by AstraZeneca, a grant of GBP 493,877 in January 2023, and a Series D of $80 million in July 2024 with investors like AstraZeneca and Leaps by Bayer, achieving a near $1 billion valuation and total raised over $290-300 million.
Jan 2016SeedDale Ventures; Iratel Ventures; Healthbox$1M--

Who has invested in Huma?

13 investors have backed Huma across its funding rounds, including Leaps by Bayer, Hitachi Ventures, AstraZeneca, Healthbox, NWS Holdings and HAT Sicaf.

Lead investors include AstraZeneca, Hitachi Ventures, Leaps by Bayer and NWS Holdings.


Huma Investors

Investors in Huma by funding rounds participated
InvestorHQRoundsRoleFirst check
Leaps by BayerGermanyLeverkusen3LeadNov 2019
NWS HoldingsHong KongHong Kong2LeadFeb 2018
AstraZenecaUnited KingdomCambridge2LeadMar 2022
HAT SicafItalyMilan2ParticipantMay 2021
Hitachi VenturesGermanyMunich2LeadMay 2021
HealthboxUnited StatesChicago, IL2ParticipantJan 2016
Unilever VenturesUnited KingdomLondon1ParticipantMay 2021
Samsung NEXTUnited StatesSan Francisco, CA1ParticipantMay 2021
Nikesh AroraUnited StatesSan Jose, CA1ParticipantMay 2021
Dale VenturesUAEDubai1ParticipantJan 2016
Iratel VenturesUnited KingdomLondon1ParticipantJan 2016

This data is available for Pro users. Sign up to see all 13 Huma investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by Huma

Huma has acquired 7 companies to date.

Last acquisition by Huma was on May 16th 2025. Huma acquired Aluna for undisclosed valuation.


Latest Acquisitions by Huma

Aluna
eConsult Health
Alcedis
iPlato Healthcare
Description
Aluna is a San Francisco-headquartered technology company transforming respiratory care with machine learning. Its self-management system converts hospital-grade spirometers into portable devices paired with apps for asthma and COPD patients, enabling daily monitoring without clinician oversight. Launched in 2019, it processes spirometry data to predict exacerbations and has partnerships with health systems in the US and Europe.
eConsult Health is a US-based digital platform providing asynchronous eConsults for primary and specialist care triage. Headquartered in Santa Monica, it enables clinicians to consult specialists via secure messaging with image uploads, reducing in-person visits by 40 percent. Founded in 2010, the system serves health systems like Kaiser Permanente and Veterans Health Administration across 40 states. eConsult Health processes over 1 million consults annually, integrating with EHRs such as Epic and Cerner for workflow efficiency.
-
iPlato Healthcare is a London-based developer of the myGP patient engagement platform used by over 200 UK GP practices. Launched in 2013, the app enables online consultations, prescription requests, and appointment booking for 1.5 million patients monthly. Integrated with NHS systems, myGP supports video triage and chronic disease management tools, reducing no-show rates by 30 percent in adopting clinics. The platform complies with GDPR and processes 500,000 interactions weekly across primary care networks.
HQ CountryUnited StatesUnited KingdomGermanyUnited Kingdom
HQ City
San Francisco, CA
London
Frankfurt
London
Deal Date16 May 20252 Oct 20249 Jan 202320 Jan 2022
Valuationundisclosed$950Mundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Huma acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Huma

Huma has invested in 1 company to date.

Latest investment by Huma was on September 23rd 2026. Huma invested in ViferaXS in their $14M Series A round.


Latest Investments by Huma

ViferaXS
Description
ViferaXS is a biotechnology company that formulates peptide-based antigens and adjuvants for oncology immunotherapy.
HQ CountryGermany
HQ City
Tübingen
Deal Date23 Sep 2026
RoundSeries A
Raised$14M
InvestorsSPRIN-D
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Huma investments and their VC round multiples.

Start Free Trial

Huma Competitors

Huma competitors include listed companies like GoodRx and Ping An Healthcare, and private ones like DocPlanner, Forward, Miaoshou Doctor and Midi Health.

Public and private companies comparable to Huma
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
DocPlannerPolandWarsawPrivate--$1B-
ForwardUnited StatesSan Francisco, CAPrivate--$1B-
Miaoshou DoctorChinaBeijingPrivate--$1B-
Midi HealthUnited StatesLos Angeles, CAPrivate$150M-$1B6.7x
GoodRxUnited StatesUnited StatesPublicly listed$797M$173M$1.2B1.8x
Ping An HealthcareChinaChinaPublicly listed$822M$52M$1.5B0.7x

Huma Public Comps

Huma is still privately-owned, but its public comps include GoodRx, Ping An Healthcare, JMDC, Medley Inc., Teladoc, Guiyang Longmaster, American Well, LifeMD, Kooth and Nyxoah.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
GoodRx$797M$173M1.8x1.8x8.3x5.7x
Ping An Healthcare$822M$52M0.7x0.7x10.4x14.6x
JMDC$320M$87M5.1x4.6x18.9x17.9x
Medley Inc.$233M$32M2.1x1.8x15.8x12.9x
Teladoc$2.5B$124M0.7x0.7x14.0x6.0x
Guiyang Longmaster$45M$5M9.1x-80.3x-
American Well$249M($63M)0.1x0.2x(0.6x)(2.8x)
LifeMD$194M($2M)0.5x0.4x(60.2x)(105.6x)

This data is available for Pro users. Sign up to see all Huma competitors and their valuation data.

Start Free Trial

Common questions about Huma

When was Huma founded?Huma was founded in 2011.
Where is Huma headquartered?Huma is headquartered in London, United Kingdom.
Is Huma publicly listed?No, Huma is a private, VC-backed company.
What is Huma's valuation?Huma was last valued at $1B in its Series D in July 2024.
How much funding has Huma raised?Huma has raised $292M across 6 funding rounds.
What was Huma's last funding round?Huma's last funding round was a $80M Series D in July 2024.
Who are Huma's investors?Huma's investors include Leaps by Bayer, NWS Holdings, AstraZeneca, HAT Sicaf, Hitachi Ventures, Healthbox, Unilever Ventures, Samsung NEXT, Nikesh Arora, Dale Ventures and 3 others.
Which companies are comparable to Huma?Companies comparable to Huma include DocPlanner, Forward, Miaoshou Doctor, Midi Health, GoodRx and Ping An Healthcare.
How many companies has Huma acquired?Huma has acquired 7 companies, including Aluna, eConsult Health, Alcedis, iPlato Healthcare and Tarilian Laser Technologies.
What was the largest acquisition by Huma?The $950M acquisition of eConsult Health in October 2024 is the largest acquisition Huma has made to date.
How many companies has Huma invested in?Huma has invested in 1 company, including ViferaXS.
What was Huma's last investment?In September 2026, Huma invested in ViferaXS's $14M Series A alongside SPRIN-D.

See companies similar to Huma

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial